Free shipping on all orders over $ 500


Cat. No. M6206
ARV-825 Structure
Size Price Availability Quantity
1mg USD 100 In stock
5mg USD 230 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

ARV-825 is a hetero-bifunctional proteolysis-targeting chimera (PROTAC) that recruits BRD4 to the E3 ubiquitin ligase cereblon. ARV-825 actively recruits BRD4 to cereblon, resulting in the rapid and efficient degradation of the former via the proteasome. Given that BRD4 and cereblon binding moieties in ARV-825 have Kds of 28-90 nM and ~3 µM to their respective targets, this suggests that ARV-825 acts in a substoichiometric way in mediating BRD4 degradation. ARV-825 treatment results in prolonged BRD4 down-regulation and downstream signaling suppression compared to BRD4 inhibitors.

Cell Experiment
Cell lines SKO-007(J3) cells
Preparation method Lysates of SKO-007(J3) cells, untreated or treated with ARV-825 (0.2 μM), lenalidomide (10 μM), or the combination of the two drugs for 24 h, were subjected to Western blotting using anti-BRD4 or anti-p85 antibodies.
Concentrations 0.2 μM
Incubation time 48 h
Animal Experiment
Animal models
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 923.43
Formula C46H47ClN8O9S
CAS Number 1818885-28-7
Purity 99.91%
Solubility DMSO 45 mg/mL
Storage at -20°C

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Saenz DT, et al. Leukemia. 2017 Sep;31(9):1951-1961. PMID: 28042144.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP, et al. J Hematol Oncol. 2016 Dec 1;9(1):134. PMID: 27903272.

Related Epigenetic Reader Domain Products

KG-501 is a cAMP response element-binding protein (CREB) inhibitor with IC50 of 6.89 μM.


AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor, with IC50 value of 5 nM.


MS417 (also known as GTPL7512) is a potent and selective BRD4 inhibitor, which binds to BRD4-BD1 and BRD4-BD2 with IC50s of 30 and 46 nM, respectively.


FL-411 is a selective BRD4 inhibitor.


dBET6 is a highly potent, selective and cell-permeable degrader of BET with an IC50 of 14 nM.

Abmole Inhibitor Catalog 2017

Keywords: ARV-825 supplier, Epigenetic Reader Domain, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.